Ibrance trial failure dashes Pfizer’s growth hopes for the drugPfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set Share XIbrance trial failure dashes Pfizer’s growth hopes for the drughttps://pharmaphorum.com/news/ibrance-trial-failure-dashes-pfizers-growth-hopes-for-the-drug/
Lilly’s Verzenio fails in KRAS-mutated lung cancerLilly’s Verzenio has failed to show benefits in lung cancer patients with a KRAS mutation, denting the company’s Share XLilly’s Verzenio fails in KRAS-mutated lung cancerhttps://pharmaphorum.com/news/verzenio-fails-lung-cancer/
